Clinical and molecular phenotypes of low-penetrance variants of NLRP3: diagnostic and therapeutic challenges
Objective Cryopyrin-associated periodic syndromes (CAPS) result from gain-of-function mutations in the NLRP3 gene, which causes excessive release of interleukin-1β (IL-1β) and systemic inflammation. While pathogenetic NLRP3 variant phenotypes are well-characterized, low-penetrance NLRP3 variants rep...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
November 2017
|
| In: |
Arthritis & rheumatology
Year: 2017, Jahrgang: 69, Heft: 11, Pages: 2233-2240 |
| ISSN: | 2326-5205 |
| DOI: | 10.1002/art.40208 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1002/art.40208 Verlag, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40208 
|
| Verfasserangaben: | J.B. Kuemmerle‐Deschner, D. Verma, T. Endres, L. Broderick, A.A. de Jesus, F. Hofer, N. Blank, K. Krause, C. Rietschel, G. Horneff, I. Aksentijevich, P. Lohse, R. Goldbach‐Mansky, H.M. Hoffman, S.M. Benseler |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1584493887 | ||
| 003 | DE-627 | ||
| 005 | 20230427161330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181127s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/art.40208 |2 doi | |
| 035 | |a (DE-627)1584493887 | ||
| 035 | |a (DE-576)514493887 | ||
| 035 | |a (DE-599)BSZ514493887 | ||
| 035 | |a (OCoLC)1341024231 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kümmerle-Deschner, Jasmin |d 1964- |e VerfasserIn |0 (DE-588)102241092X |0 (DE-627)716964546 |0 (DE-576)17222442X |4 aut | |
| 245 | 1 | 0 | |a Clinical and molecular phenotypes of low-penetrance variants of NLRP3 |b diagnostic and therapeutic challenges |c J.B. Kuemmerle‐Deschner, D. Verma, T. Endres, L. Broderick, A.A. de Jesus, F. Hofer, N. Blank, K. Krause, C. Rietschel, G. Horneff, I. Aksentijevich, P. Lohse, R. Goldbach‐Mansky, H.M. Hoffman, S.M. Benseler |
| 264 | 1 | |c November 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 27.11.2018 | ||
| 520 | |a Objective Cryopyrin-associated periodic syndromes (CAPS) result from gain-of-function mutations in the NLRP3 gene, which causes excessive release of interleukin-1β (IL-1β) and systemic inflammation. While pathogenetic NLRP3 variant phenotypes are well-characterized, low-penetrance NLRP3 variants represent a significant clinical challenge. The aims of this study were to determine the clinical phenotype, the in vitro biologic phenotype, and the effect of anti-IL-1 treatment in patients with low-penetrance NLRP3 variants. Methods A multicenter study of consecutive symptomatic patients with low-penetrance NLRP3 variants recruited from 7 centers between May 2012 and May 2013 was performed. The observed findings were transferred into a study database, from which they were extracted for analysis. Controls were patients with a known pathogenetic NLRP3 variant. Clinical presentation and CAPS markers of inflammation were captured. Functional assays of inflammasome activation, including caspase 1 activity, NF-κB release, cell death, and IL-1β release, were performed. Treatment effects of IL-1 were determined. Comparisons between low-penetrance and pathogenetic NLRP3 variants were performed. Results The study included 45 patients, 21 of which were female (47%); 26 of the patients (58%) were children. NLRP3 low-penetrance variants identified in the patients were Q703K (n = 19), R488K (n = 6), and V198M (n = 20). In the controls, 28 had pathogenetic NLRP3 variants. Patients with low-penetrance NLRP3 variants had significantly more fever (76%) and gastrointestinal symptoms (73%); eye disease, hearing loss, and renal involvement were less common. Functional inflammasome testing identified an intermediate phenotype in low-penetrance NLRP3 variants as compared to wild-type and pathogenetic NLRP3 variants. All treated patients responded to IL-1 inhibition, with complete response documented in 50% of patients. Conclusion Patients with low-penetrance NLRP3 variants display a distinct clinical phenotype and an intermediate biologic phenotype, including IL-1β and non-IL-1β-mediated inflammatory pathway activation. | ||
| 700 | 1 | |a Blank, Norbert |d 1964- |e VerfasserIn |0 (DE-588)115586032 |0 (DE-627)691431507 |0 (DE-576)289963508 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Arthritis & rheumatology |d Hoboken, NJ : Wiley, 2014 |g 69(2017), 11, Seite 2233-2240 |h Online-Ressource |w (DE-627)777780615 |w (DE-600)2754614-7 |w (DE-576)400527065 |x 2326-5205 |7 nnas |a Clinical and molecular phenotypes of low-penetrance variants of NLRP3 diagnostic and therapeutic challenges |
| 773 | 1 | 8 | |g volume:69 |g year:2017 |g number:11 |g pages:2233-2240 |g extent:8 |a Clinical and molecular phenotypes of low-penetrance variants of NLRP3 diagnostic and therapeutic challenges |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/art.40208 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/art.40208 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181127 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 115586032 |a Blank, Norbert |m 115586032:Blank, Norbert |d 910000 |d 910100 |e 910000PB115586032 |e 910100PB115586032 |k 0/910000/ |k 1/910000/910100/ |p 7 | ||
| 999 | |a KXP-PPN1584493887 |e 3034156952 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Kümmerle-Deschner","display":"Kümmerle-Deschner, Jasmin","given":"Jasmin","role":"aut"},{"family":"Blank","display":"Blank, Norbert","given":"Norbert","role":"aut"}],"name":{"displayForm":["J.B. Kuemmerle‐Deschner, D. Verma, T. Endres, L. Broderick, A.A. de Jesus, F. Hofer, N. Blank, K. Krause, C. Rietschel, G. Horneff, I. Aksentijevich, P. Lohse, R. Goldbach‐Mansky, H.M. Hoffman, S.M. Benseler"]},"physDesc":[{"extent":"8 S."}],"id":{"eki":["1584493887"],"doi":["10.1002/art.40208"]},"note":["Gesehen am 27.11.2018"],"relHost":[{"titleAlt":[{"title":"Arthritis and rheumatology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"2014","publisher":"Wiley","dateIssuedDisp":"2014-","publisherPlace":"Hoboken, NJ"}],"recId":"777780615","disp":"Clinical and molecular phenotypes of low-penetrance variants of NLRP3 diagnostic and therapeutic challengesArthritis & rheumatology","id":{"eki":["777780615"],"zdb":["2754614-7"],"issn":["2326-5205"]},"physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"display":"American College of Rheumatology","role":"isb"}],"pubHistory":["66.2014 -"],"title":[{"subtitle":"an official journal of the American College of Rheumatology","title":"Arthritis & rheumatology","title_sort":"Arthritis & rheumatology"}],"part":{"year":"2017","text":"69(2017), 11, Seite 2233-2240","volume":"69","pages":"2233-2240","extent":"8","issue":"11"},"language":["eng"]}],"recId":"1584493887","origin":[{"dateIssuedDisp":"November 2017","dateIssuedKey":"2017"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title_sort":"Clinical and molecular phenotypes of low-penetrance variants of NLRP3","title":"Clinical and molecular phenotypes of low-penetrance variants of NLRP3","subtitle":"diagnostic and therapeutic challenges"}],"language":["eng"]} | ||
| SRT | |a KUEMMERLEDCLINICALAN2017 | ||